Dr. Di Paola is a Tenured Professor of Pediatrics and Division Chief of Pediatric Hematology Oncology at Washington University School of Medicine in St. Louis and the Associate Director of the Washington University School of Medicine Medical Scientist Training Program. His previous Faculty appointments were at the University of Iowa and the University of Colorado. Dr. Di Paola’s research focuses on the genetics and biology of bleeding and thrombotic disorders. His laboratory has made significant discoveries in von Willebrand disease, platelet disorders and cancer predisposition. These discoveries have set the stage for potential new therapies. Dr. Di Paola has published more than 150 original scientific articles, reviews and book chapters and is Associate Editor of Blood.

Dr Amanda Davis is a haematologist and transfusion specialist at The Alfred. She manages complex adult patients with hereditary and acquired bleeding disorders through the Ronald Sawers Haemophilia Treatment Centre as well as patients with thrombotic disorders and patients with a variety of other haematological conditions. She also works in the diagnostic haematology laboratory at The Alfred. Dr Davis chairs the hospital Transfusion Committee as well as chairing the Victorian Haemovigilance Program – Serious Transfusion Incident Reporting System (STIR). She completed her medical degree with honours at Monash University in 1996 and acquired a dual fellowship in Clinical and Laboratory Haematology in 2005. She then undertook a fellowship in Transfusion Medicine at Harvard Medical School in Boston with a research focus on investigating vascular binding partners of ADAMTS13, an important regulator of von Willebrand factor size and function and a critical contributor to the pathogenesis of inherited and acquired forms of thrombotic thrombocytopenic purpura.

Chee Wee Tan, haematologist at the Royal Adelaide Hospital and Clinical Director of SA Pathology, is President of the THANZ, co-contributor to the AUS/NZ ITP Treatment Guidelines, and member of ITP Australia Medical Advisory Board. He's also part of the AHCDO Executive Committee. Interests include heparin-induced thrombocytopenia and platelet activation.